Lori Kunkel, M.D. holds more than twenty years of experience in oncology and immunology drug development and commercialization. From October 2013 to October 2014 she was the acting chief medical officer of Loxo Oncology, Inc. Prior to that role she was the chief medical officer of Pharmacyclics LLC, acquired by AbbVie; the chief medical officer of Proteolix, Inc., acquired by Onyx Pharmaceuticals; and the vice president of Clinical Development at Xencor, Inc., each a biopharmaceutical company. Prior to these positions she was a clinical scientist at Genentech, a biopharmaceutical company, where she worked on the development of RITUXAN ®. Additionally, as a clinical drug development specialist, Dr. Kunkel has advised multiple clients including Chiron, Genentech/Roche, Salmedics, and currently is an advisor to Stemcentrx, Inc. and Amphivena Therapeutics, each a biopharmaceutical company. Prior to joining the biotechnology industry, Dr. Kunkel spent ten years in academic medicine and served as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at University of California, Los Angeles.
Dr. Kunkel currently serves on the board of Tocagen (Nasdaq: TOCA) and Curis, Inc. (Nasdaq: CRIS), and served on the board of Loxo Oncology (Nasdaq: LOXO) until its $8 Billion sale to Eli Lilly.
Dr. Kunkel received her medical degree from University of Southern California and her bachelor’s degree in biology from University of California, San Diego. She is board certified in internal medicine and held board certifications in hematology and oncology.